<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00058032</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000285690</org_study_id>
    <secondary_id>UKCTOCS</secondary_id>
    <secondary_id>EU-20249</secondary_id>
    <nct_id>NCT00058032</nct_id>
  </id_info>
  <brief_title>CA125 and Ultrasound in Detecting Ovarian Cancer in Postmenopausal Women</brief_title>
  <acronym>UKCTOCS</acronym>
  <official_title>United Kingdom Collaborative Trial Of Ovarian Cancer Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Eve Appeal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Screening tests may help doctors detect ovarian cancer early when the survival is&#xD;
      much more encouraging. It is not yet known whether a CA125-based or ultrasound strategy is&#xD;
      more effective in detecting ovarian cancer early thereby impacting on the mortality from the&#xD;
      disease in postmenopausal women from the general population.&#xD;
&#xD;
      PURPOSE: Randomized clinical trial to assess the impact of screening using a multimodal&#xD;
      strategy using CA125 interpreted by the Risk of Ovarian Cancer Algorithm (ROCA) followed by&#xD;
      transvaginal ultrasound as a second line test versus transvaginal ultrasound on mortality&#xD;
      from the disease in postmenopausal women from the general population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the impact of preclinical detection of ovarian cancer by screening on ovarian&#xD;
           cancer mortality in postmenopausal women.&#xD;
&#xD;
        -  Determine the physical morbidity of ovarian cancer screening in this population.&#xD;
&#xD;
        -  Determine the psychological consequences of screening results (true negative, true&#xD;
           positive, false negative, and false positive) in this population.&#xD;
&#xD;
        -  Compare the interventions that result from screening for ovarian cancer using CA 125&#xD;
           monitoring and ultrasound in this population.&#xD;
&#xD;
        -  Compare the feasibility of population screening, in terms of compliance rates with&#xD;
           annual screening for ovarian cancer with these strategies.&#xD;
&#xD;
        -  Compare the performance of these screening strategies in this population.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Participants are randomized to 1 of 3&#xD;
      screening arms.&#xD;
&#xD;
        -  Arm I: Participants do not undergo screening.&#xD;
&#xD;
        -  Arm II: Participants undergo screening with an annual CA 125 level interpreted using the&#xD;
           Risk of Ovarian Cancer Algorithm (ROCA). Depending on the results of the test, some&#xD;
           patients may undergo additional screening.&#xD;
&#xD;
        -  Arm III: Participants undergo screening with an annual transvaginal or transabdominal&#xD;
           ultrasound. Depending on the results of the test, some patients may undergo additional&#xD;
           screening.&#xD;
&#xD;
      Participants in all arms complete a health questionnaire at 3-5 years after study entry and&#xD;
      in 2014.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 200,000 participants (100,000 for arm I and 50,000 each for&#xD;
      arms II and III) will be accrued for this study within 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 17, 2001</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">September 29, 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>202,638 participants randomised to: Multimodal Group: 50640 Ultrasound Group: 50639 Control Group: 101359</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>UKCTOCS (2001-2014): Death due to ovarian cancer (WHO 2003) determined by independent outcomes committee review of patient notes for all women identified to have a 'possible ovarian cancer' (pre-specified ICD-10 codes) till 31st December 2014.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Long term impact of screening on ovarian cancer mortality in the UKCTOCS (LTFU UKCTOCS) (2015-2021): Death due to ovarian cancer (WHO 2014) determined by independent outcomes committee review till 30 June 2020.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance characteristics: Sensitivity, specificity, positive predictive values of the two screening strategies (multimodal and ultrasound) for detection of ovarian cancer diagnosed within one year of last screen.</measure>
    <description>Ovarian cancer diagnosis is based on outcomes review of medical notes of all women who developed ovarian cancer during the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical complications in women who underwent false positive surgery and were found to have benign or normal adnexae.</measure>
    <description>This is assessed through central medical note review and assigned by designated trial gynaecological oncologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectivenesss of the multimodal (MMS) and ultrasound screening (USS) strategies separately comparing them to a no-screening arm.</measure>
    <description>Cost-effectivenesss of the multimodal (MMS) and ultrasound screening (USS) strategies separately comparing them to a no-screening arm: (a) Incremental cost-effectiveness analysis over the 14 year period of the trial (censorship 31st Dec 2014); (b) Incremental cost-effectiveness analysis for the cumulative mortality estimated over a 25-year period by extrapolating beyond the 14 years of the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance with annual screening: The proportion of women who attended all tests that formed part of an annual screening episode of the total who were eligible for that annual screening episode.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychological morbidity related to screening - assessed in a separate MRC funded study, UKCTOCS Psychosocial study, PI Prof Dame Lesley Fallowfield.</measure>
  </secondary_outcome>
  <enrollment type="Actual">202638</enrollment>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>screening questionnaire administration</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>annual screening</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Postmenopausal, as defined by meeting 1 of the following criteria:&#xD;
&#xD;
               -  More than 12 months of amenorrhea after natural menopause or hysterectomy&#xD;
&#xD;
               -  Received more than 12 months of hormone replacement therapy for menopausal&#xD;
                  symptoms&#xD;
&#xD;
          -  No prior ovarian malignancy&#xD;
&#xD;
          -  No prior bilateral oophorectomy&#xD;
&#xD;
          -  Not at high risk for ovarian cancer due to familial predisposition as defined by the&#xD;
             UKCCCR Familial Ovarian Cancer Screening Study&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  50 to 74&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No active non-ovarian malignancy&#xD;
&#xD;
               -  Prior malignancy allowed provided there is no documented persistent or recurrent&#xD;
                  disease and patient has not received treatment for more than 1 year&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent participation in any other ovarian cancer screening study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Usha Menon, MBBS, MRCOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <results_reference>
    <citation>Jacobs I, Gentry-Maharaj A, Burnell M, Manchanda R, Singh N, Sharma A, Ryan A, Seif MW, Amso NN, Turner G, Brunell C, Fletcher G, Rangar R, Ford K, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Scott I, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Leeson S, Cruickshank D, Skates SJ, Fallowfield L, Parmar M, Campbell S, Menon U. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol. 2011 Jan;12(1):38-48. doi: 10.1016/S1470-2045(10)70268-0. Epub 2010 Dec 10.</citation>
    <PMID>21147030</PMID>
  </results_reference>
  <results_reference>
    <citation>Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009 Apr;10(4):327-40. doi: 10.1016/S1470-2045(09)70026-9. Epub 2009 Mar 11.</citation>
    <PMID>19282241</PMID>
  </results_reference>
  <results_reference>
    <citation>Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, Crump DN, Davies SK, Dawnay A, Dobbs S, Fletcher G, Ford J, Godfrey K, Gunu R, Habib M, Hallett R, Herod J, Jenkins H, Karpinskyj C, Leeson S, Lewis SJ, Liston WR, Lopes A, Mould T, Murdoch J, Oram D, Rabideau DJ, Reynolds K, Scott I, Seif MW, Sharma A, Singh N, Taylor J, Warburton F, Widschwendter M, Williamson K, Woolas R, Fallowfield L, McGuire AJ, Campbell S, Parmar M, Skates SJ. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016 Mar 5;387(10022):945-956. doi: 10.1016/S0140-6736(15)01224-6. Epub 2015 Dec 17. Erratum in: Lancet. 2016 Mar 5;387(10022):944. Erratum in: Lancet. 2016 Mar 5;387(10022):944.</citation>
    <PMID>26707054</PMID>
  </results_reference>
  <results_reference>
    <citation>Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, Apostolidou S, Singh N, Benjamin E, Burnell M, Davies S, Sharma A, Gunu R, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Seif MW, Jenkins H, Mould T, Woolas R, Murdoch JB, Dobbs S, Amso NN, Leeson S, Cruickshank D, Scott I, Fallowfield L, Widschwendter M, Reynolds K, McGuire A, Campbell S, Parmar M, Skates SJ, Jacobs I. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol. 2015 Jun 20;33(18):2062-71. doi: 10.1200/JCO.2014.59.4945. Epub 2015 May 11.</citation>
    <PMID>25964255</PMID>
  </results_reference>
  <results_reference>
    <citation>Menon U, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, Lewis S, Lopez A, Godfrey K, Oram D, Herod J, Williamson K, Seif M, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso N, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Skates S, Parmar M, Jacobs I. Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study. BMJ. 2008 Nov 13;337:a2079. doi: 10.1136/bmj.a2079. Erratum in: BMJ. 2008;337:a2976.</citation>
    <PMID>19008269</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 7, 2003</study_first_submitted>
  <study_first_submitted_qc>April 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2003</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian epithelial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

